UNICA IRIS Institutional Research Information System

PUZZONI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 60.550
NA - Nord America 4.061
AS - Asia 1.971
SA - Sud America 305
Continente sconosciuto - Info sul continente non disponibili 198
AF - Africa 59
OC - Oceania 4
Totale 67.148
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 59.675
US - Stati Uniti d'America 3.919
SG - Singapore 862
CN - Cina 524
BR - Brasile 227
VN - Vietnam 222
SE - Svezia 215
DE - Germania 128
FR - Francia 101
GB - Regno Unito 86
FI - Finlandia 82
CA - Canada 71
HK - Hong Kong 71
IN - India 68
UA - Ucraina 68
NL - Olanda 51
BD - Bangladesh 31
KR - Corea 24
JP - Giappone 23
MX - Messico 23
PL - Polonia 22
AR - Argentina 21
RU - Federazione Russa 21
AT - Austria 20
ES - Italia 20
IQ - Iraq 20
TR - Turchia 18
ZA - Sudafrica 17
EC - Ecuador 16
CO - Colombia 15
ID - Indonesia 14
PK - Pakistan 14
IE - Irlanda 13
VE - Venezuela 13
IL - Israele 12
MA - Marocco 12
CR - Costa Rica 11
BE - Belgio 10
PH - Filippine 8
AE - Emirati Arabi Uniti 7
IR - Iran 7
KG - Kirghizistan 7
UZ - Uzbekistan 7
SA - Arabia Saudita 6
TN - Tunisia 6
GT - Guatemala 5
SC - Seychelles 5
SV - El Salvador 5
TH - Thailandia 5
AU - Australia 4
CL - Cile 4
CW - ???statistics.table.value.countryCode.CW??? 4
CZ - Repubblica Ceca 4
EG - Egitto 4
JM - Giamaica 4
KE - Kenya 4
MK - Macedonia 4
PE - Perù 4
TT - Trinidad e Tobago 4
GP - Guadalupe 3
GR - Grecia 3
HN - Honduras 3
LT - Lituania 3
LV - Lettonia 3
MY - Malesia 3
NI - Nicaragua 3
NP - Nepal 3
PY - Paraguay 3
RS - Serbia 3
AL - Albania 2
AM - Armenia 2
BB - Barbados 2
BO - Bolivia 2
CH - Svizzera 2
DM - Dominica 2
DZ - Algeria 2
HU - Ungheria 2
KZ - Kazakistan 2
LU - Lussemburgo 2
NG - Nigeria 2
NO - Norvegia 2
OM - Oman 2
PR - Porto Rico 2
PT - Portogallo 2
BH - Bahrain 1
BS - Bahamas 1
BZ - Belize 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
EU - Europa 1
GA - Gabon 1
GD - Grenada 1
GE - Georgia 1
HR - Croazia 1
LB - Libano 1
LK - Sri Lanka 1
LY - Libia 1
ML - Mali 1
Totale 66.944
Salva come PNG Salva come JPEG
Città #
Cagliari 57.741
Uta 1.551
Ashburn 520
Singapore 508
San Jose 309
Dallas 300
Fairfield 245
Boardman 157
Woodbridge 133
Houston 129
Nyköping 129
Seattle 114
Beijing 113
Chandler 111
New York 109
Council Bluffs 105
Los Angeles 99
Cambridge 87
Wilmington 77
Santa Clara 73
Dearborn 69
Ho Chi Minh City 66
Hong Kong 62
Helsinki 56
The Dalles 53
Ann Arbor 51
Rome 46
Hanoi 42
Shanghai 39
Boston 38
Lauterbourg 38
Chicago 34
Orem 31
Jacksonville 30
Dong Ket 28
Buffalo 27
São Paulo 27
Amsterdam 26
Munich 26
Frankfurt am Main 25
Hefei 25
Columbus 23
Nanjing 23
Seoul 23
London 22
Milan 22
Phoenix 19
Redondo Beach 19
San Diego 19
Toronto 19
Guangzhou 18
Nuremberg 18
Warsaw 18
Atlanta 16
Montreal 15
Paris 15
Pune 14
Tokyo 14
Brooklyn 13
Shenyang 13
Denver 12
Düsseldorf 12
Hangzhou 12
Turku 12
Chennai 11
Naples 11
Poplar 11
Zhengzhou 11
Dublin 10
Stockholm 10
San José 9
Tianjin 9
Vienna 9
Casablanca 8
Changsha 8
Da Nang 8
Haiphong 8
Mont-saint-hilaire 8
Rio de Janeiro 8
Shenzhen 8
Wuhan 8
Augusta 7
Baghdad 7
Bishkek 7
Charlotte 7
Jiaxing 7
Johannesburg 7
Medellín 7
Mumbai 7
Salt Lake City 7
Tashkent 7
Belo Horizonte 6
Birmingham 6
Biên Hòa 6
Buenos Aires 6
Hải Dương 6
Nanchang 6
New Delhi 6
Portsmouth 6
Quito 6
Totale 64.119
Salva come PNG Salva come JPEG
Nome #
Pathophysiology of cardiotoxicity induced by nonanthracycline chemotherapy 4.191
Clustered protocadherins methylation alterations in cancer 3.350
BRAF-mutant colorectal cancer, a different breed evolving 3.259
Regorafenib-induced hypothyroidism and cancer-related fatigue: is there a potential link? 3.012
Molecular-biology-driven treatment for metastatic colorectal cancer 2.795
HOXD8 hypermethylation as a fully sensitive and specific biomarker for biliary tract cancer detectable in tissue and bile samples 2.733
Thyroid dysfunction in disguise and treatment-related fatigue in the spotlight among metastatic colorectal cancer patients receiving regorafenib: Implications for clinical management. 2.663
Alterazioni tiroidee funzionali e morfologiche in pazienti affetti da carcinoma del colon-retto metastatico in trattamento con Regorafenib. Risultati di uno studio prospettico. 2.495
Colorectal cancer early detection in stool samples tracing CPG islands methylation alterations affecting gene expression 2.393
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis 2.358
The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab 2.151
Prognostic Value of Thyroid Hormone Ratios in Patients With Advanced Metastatic Colorectal Cancer Treated With Regorafenib: The TOREADOR Study 2.132
The immune revolution in gastrointestinal tumours: leading the way or just following? 1.989
Critical features and challenges associated with imaging in patients undergoing cancer immunotherapy 1.704
Immunotherapy and Cancer: The Multi-Omics Perspective 1.648
Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials 1.644
Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients? 1.557
Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications 1.425
Hepatocellular carcinoma and microbiota: Implications for clinical management and treatment 1.384
The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors 1.352
Second-line chemotherapy for advanced pancreatic cancer: Which is the best option? 1.305
Immunotherapy for colorectal cancer: where are we heading? 1.288
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial 1.277
Molecular-driven treatment for biliary tract cancer: the promising turning point 1.244
CDX-2 expression correlates with clinical outcomes in MSI-H metastatic colorectal cancer patients receiving immune checkpoint inhibitors 1.112
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma: Myth or Reality? 1.106
Antiangiogenic agents after first line and sorafenib plus chemoembolization: A systematic review 1.026
Neoadjuvant chemo-radiotherapy response in patients affected by mismatch repair deficient (dMMR) locally advanced rectal cancer 1.006
Liquid Biopsy-Driven Cetuximab Rechallenge Strategy in Molecularly Selected Metastatic Colorectal Cancer Patients 978
Thyroid hormones ratio is a major prognostic marker in advanced metastatic colorectal cancer: Results from the phase III randomised CORRECT trial 967
New Horizons in Metastatic Colorectal Cancer: Prognostic Role of CD44 Expression 922
Corrigendum: Why precision medicine should be applied across the continuum of care for metastatic colorectal cancer patients 793
Circulating tumour DNA in gastrointestinal cancer in clinical practice: Just a dream or maybe not? 777
Cholangiocarcinoma: new perspectives for new horizons 755
Uncovering key targets of success for immunotherapy in pancreatic cancer 742
Prediction of Response to Anti-Angiogenic Treatment for Advanced Colorectal Cancer Patients: From Biological Factors to Functional Imaging 637
Correction to: Angiogenesis Genotyping and Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib: The ALICE‑2 Study 518
Patients with early-onset metastatic colorectal cancer as an emerging distinctive clinical and molecular phenomenon 458
Selection with a molecUlar PanEl foR Panitumumab EfficAcy in K-RAS and N-RAS wild type metastatic colorectal cancer (SUPER-PEAK) 357
CD44: A New Prognostic Marker in Colorectal Cancer? 293
A new prognostic score for biliary tract cancer: a multicenter experience 238
REINVENT (REgorafenIb traNslational eValuation angiogENesis proTocol) 236
Mismatch repair proteins (MMR) expression as predictive factor in locally advanced rectal cancer 231
Clinical Outcome of Patients With Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment 221
Thyroid dysfunction and immune checkpoint inhibitors: Effect on survival in elderly patients 220
Navigating the Landscape of Liquid Biopsy in Colorectal Cancer: Current Insights and Future Directions 209
Fentanyl pectin nasal spray for breakthrough cancer pain treatment: a single center experience 201
Medical management of malignant bowel obstruction: our center experience 198
Overall survival and progression-free survival in metastatic colorectal cancer patients with concomitant RAS and BRAF mutations: a single center experience 184
LONG-TERM RESPONSE TO SUNITINIB, EVEROLIMUS AND AXITINIB SEQUENTIALLY USED IN A YOUNG WOMEN WITH MRCC. A CASE REPORT 165
Preoperatory FLOT Regimen for Gastroesophageal Cancer and Renal Function: A New Onco-Nephrological Perspective 162
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile 157
Clinical characteristics and outcomes in patients with early-onset locally advanced rectal cancer 157
Clinical and molecular features of early-onset metastatic pancreatic cancer and their impact on therapeutic sequences: A multicenter study 139
Influence of levothyroxine concomitant treatment on treatment responses and outcomes in patients with metastatic colorectal adenocarcinoma 137
The correlation between L1CAM expression and outcomes in patients with metastatic colorectal cancer treated with first-line chemotherapy 136
Comparison between different therapeutic sequences in patients affected by metastatic pancreatic ductal adenocarcinoma 123
Lymphocyte to monocyte ratio in metastatic pancreatic ductal adenocarcinoma as a prognostic factor and its potential role in identifying a subset of patients with a favorable response to therapy 120
The interconnection between cellular metabolism and lymphocyte activation as a prognostic factor in patients affected by metastatic pancreatic ductal adenocarcinoma treated with gemcitabine and nab-paclitaxel as first line 118
Totale 67.148
Salva come PNG Salva come JPEG
Categoria #
all - tutte 92.037
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 92.037
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.328 0 0 0 0 212 210 192 221 297 365 335 496
2022/20235.508 509 934 730 402 390 440 230 413 343 500 378 239
2023/20247.333 338 205 187 345 509 854 854 2.301 271 372 562 535
2024/202514.465 4.177 4.456 1.416 1.341 691 965 752 66 159 132 110 200
2025/20265.051 382 281 470 432 376 357 1.055 447 310 469 286 186
2026/2027980 80 185 225 442 48 0 0 0 0 0 0 0
Totale 67.148